SI-BONE (NASDAQ:SIBN) Given Overweight Rating at Cantor Fitzgerald

SI-BONE (NASDAQ:SIBN – Get Free Report)‘s stock had its “overweight” rating reissued by equities researchers at Cantor Fitzgerald in a report released on Tuesday, Benzinga reports. They currently have a $25.00 target price on the stock. Cantor Fitzgerald’s price objective suggests a potential upside of 36.76% from the company’s previous close. A number of other […]

Related Keywords

United States ,Anthonyj Recupero ,Timothye Davis Jr , ,Securities Exchange Commission ,Company Profile ,Morgan Stanley ,Pricet Rowe Associates Inc ,Voya Investment Management ,Needham Company ,Riverpark Advisors ,Nasdaq ,Cantor Fitzgerald ,Get Free Report ,Exchange Commission ,Director Timothy ,Investment Management ,Park Advisors ,Amalgamated Bank ,Si Bone ,Nasdaq Sibn ,Sibn ,Medical ,Reiterated Rating ,